New Blood Test Could Predict Alzheimer’s Risk Years Before Memory Loss, Scientists Say

A simple blood test that detects early biological signs of Alzheimer’s disease could eventually help identify people at risk years before they experience memory problems, according to new research. Scientists say the test may open a new chapter in Alzheimer’s prevention by allowing doctors to find individuals who could benefit from future treatments before significant brain damage occurs.

The research focuses on a blood marker known as p-tau217, a form of the tau protein linked to the development of Alzheimer’s disease. High levels of this marker appear to indicate that changes associated with the disease are already developing in the brain, even when a person still has normal memory and thinking abilities.

Researchers say the test is not yet ready to become a routine screening tool for healthy adults. However, it could become an important resource for clinical trials that are exploring whether new medicines can slow down or prevent Alzheimer’s before symptoms begin.

A Possible Early Warning System for Alzheimer’s

Alzheimer’s disease is a progressive neurological condition that affects memory, thinking, and daily functioning. For many years, scientists believed that the disease process begins long before noticeable symptoms appear. By the time memory loss becomes obvious, changes in the brain may have already been developing for years.

The new blood test could help scientists identify people who are in the earliest stages of this process.

Researchers found that older adults with the highest levels of p-tau217 had a significantly greater chance of developing cognitive problems in the future. According to the study findings, people with the highest levels of the biomarker had around a 38% likelihood of developing cognitive impairment within five years and about a 78% likelihood within ten years.

These findings suggest that the blood marker may provide clues about who is most likely to develop Alzheimer’s-related symptoms later in life.

Dr. Reisa Sperling of the Mass General Brigham Neuroscience Institute, who helped lead the study, said that testing is most valuable when there are treatments available that could change the course of the disease.

She explained that people should continue focusing on healthy lifestyle choices, including regular exercise, good sleep, a balanced diet, and staying socially and mentally active.

How the Blood Test Works

The test measures levels of p-tau217, which is connected to two major features of Alzheimer’s disease: amyloid plaques and tau tangles.

Amyloid plaques are abnormal protein deposits that build up between brain cells, while tau tangles develop inside nerve cells. Both are believed to interfere with communication between brain cells and contribute to memory decline.

Scientists believe the blood test can reveal where a person may be in this biological process.

Rather than directly measuring memory loss, the test looks for evidence of changes happening inside the brain. This could allow researchers to identify individuals who appear healthy but may already have early signs of Alzheimer’s-related changes.

Study Followed Thousands of Older Adults

The findings were based on a large long-term study involving 2,684 healthy older adults. Participants provided blood samples and completed regular cognitive assessments over nearly two decades.

During the study period, 478 participants developed cognitive impairment.

The researchers compared blood test results with later changes in memory and thinking abilities. They found that higher levels of p-tau217 were strongly associated with a greater risk of future cognitive decline.

The study was published in the medical journal JAMA and presented at the Alzheimer’s Association International Conference.

Researchers say the results provide important evidence that blood-based biomarkers may eventually become a practical way to identify people at risk of Alzheimer’s.

Experts Urge Caution Before Widespread Testing

Although the findings are promising, experts say the test still has limitations.

Doctors not involved in the research noted that the test cannot currently predict with complete certainty whether an individual will develop Alzheimer’s symptoms. Some people with elevated biomarker levels may not develop noticeable problems for many years, while others may progress differently.

Experts also warned that receiving a result showing increased risk could create anxiety if there are no available treatments to prevent the disease.

Dr. Suzanne Schindler of Washington University in St. Louis and Dr. David Wolk of the University of Pennsylvania highlighted these concerns in an accompanying editorial. They described the findings as an important step forward but noted that more research is needed.

Jessica Langbaum of the Banner Alzheimer’s Institute also said that while many people with a family history of Alzheimer’s are interested in predictive testing, the test is not currently recommended outside research settings.

Why Early Detection Matters

The potential importance of this blood test is closely connected to the development of new Alzheimer’s treatments.

Many researchers believe that future medicines may work best when given before significant memory loss occurs. Once symptoms appear, brain changes may be too advanced for some treatments to have a major effect.

A reliable early detection method could help doctors identify suitable participants for clinical trials and test whether new therapies can delay or prevent the disease.

If successful treatments become available, a blood test that identifies people at higher risk could become a key part of routine healthcare.

Lifestyle Still Plays an Important Role

Even with advances in testing technology, experts emphasize that healthy habits remain important.

Research suggests that regular physical activity, a nutritious diet, quality sleep, managing heart health, and maintaining social connections may support brain health and reduce certain risk factors associated with cognitive decline.

A future blood test may help identify risk, but it would not replace healthy lifestyle choices or medical advice.

The Future of Alzheimer’s Testing

The development of blood-based Alzheimer’s tests represents one of the most significant advances in dementia research in recent years. Scientists hope these tools will make it easier to detect the disease earlier and improve the chances of successful treatment.

For now, researchers say the test should mainly be used in carefully controlled studies. More evidence is needed before it becomes widely available to the public.

If future clinical trials show that early intervention can slow Alzheimer’s progression, blood tests like this could transform how the disease is diagnosed and treated.

Source: The independent, published July 15, 2026, and findings presented at the Alzheimer’s Association International Conference and published in JAMA.

Disclaimer: This article is for informational purposes only and does not provide medical advice, diagnosis, or treatment recommendations. Anyone concerned about Alzheimer’s risk or cognitive changes should speak with a qualified healthcare professional.